NICE to reappraise mogamulizumab for previously treated mycosis fungoides and Sézary syndrome:

NICE is to reassess mogamulizumab following an appeal launched by Kyowa Kirin, Lymphoma Action and Leukaemia Care as well as the UK Cutaneous Lymphoma Group. NICE had previously rejected mogamulizumab due to uncertain trial data.

PharmaTimes